MAY 27·SEC EDGARLow
Feld Michael sold $11K of BDX
Feld Michael (EVP, Chief Revenue Officer) sold 75 shares of BECTON DICKINSON & CO (BDX) at $147.35 on 2026-05-26 under a Rule 10b5-1 trading plan.
StockHealthcare · Medical Instruments & Supplies
$BDX
BECTON DICKINSON & CO
Price · $BDXvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 1
- Bearish
- 0
Top stories · $BDXMore →
MAY 21·BD Newsroom
BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
BD (Becton, Dickinson and Company) has launched the Elyra™ Thulium Fiber Laser (TFL) System, designed to enhance kidney stone care for urology teams. This advanced laser platform offers improved efficiency, versatility, and workflow for stone management and soft tissue procedures, featuring quiet operation and a smaller footprint. The system, available in Elyra™ and Elyra™ Plus configurations, has received positive feedback from initial clinical cases and expands BD's comprehensive portfolio for urologic stone management.
MAY 20·Simply Wall Street
How Investors May Respond To Becton Dickinson (BDX) Loss, Recall And New Interventional Leadership
Becton, Dickinson and Company (BDX) reported a Q2 net loss of US$311 million despite sales of US$4,714 million, while also affirming full-year GAAP revenue growth guidance and appointing Peter Menziuso to lead BD Interventional. The company's investment narrative now focuses on executing in higher growth franchises like BD Interventional and addressing regulatory and quality pressures highlighted by a recent microbiology pouch recall. Despite these challenges, an expanded infection-prevention partnership and solid operational growth initiatives aim to stabilize earnings, though investors are urged to consider the impact of ongoing quality scrutiny on long-term growth.